Edinburgh Research Explorer

Brian Walker

(Former employee or visitor)

  1. 11 beta HSD1-/- mice have enhanced angiogenic response and improved myodardial function following coronary artery ligation

    Small, G. R., Hadoke, P. W. F., Gray, G. A., Sharif, I., Mullins, J. J., Seckl, J. R. & Walker, B. R., Oct 2004, In : Hypertension. 44, 4, p. 587-587 1 p.

    Research output: Contribution to journalArticle

  2. 11 beta-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics

    Sandeep, T. C., Yau, J. L. W., MacLullich, A. M. J., Noble, J., Deary, I. J., Walker, B. R. & Seckl, J. R., 27 Apr 2004, In : Proceedings of the National Academy of Sciences (PNAS). 101, 17, p. 6734-6739 6 p.

    Research output: Contribution to journalArticle

  3. 11 beta-Hydroxysteroid dehydrogenase type 1 as a therapeutic target in metabolic syndrome and beyond

    Walker, B. R. & Seckl, J. R., 26 Mar 2006, In : Abstracts of Papers - American Chemical Society, National Meeting. 231, 1 p.

    Research output: Contribution to journalMeeting abstract

  4. 11 beta-Hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the intact perfused rat liver

    Jamieson, P. M., Walker, B. R., Chapman, K. E., Andrew, R., Rossiter, S. & Seckl, J. R., Jun 2000, In : Journal of Endocrinology. 165, 3, p. 685-692 8 p.

    Research output: Contribution to journalArticle

  5. 11 beta-hydroxysteroid dehydrogenase type 2 in mouse aorta - Localization and influence on response to glucocorticoids

    Christy, C., Hadoke, P. W. F., Paterson, J. M., Mullins, J. J., Seckl, J. R. & Walker, B. R., Oct 2003, In : Hypertension. 42, 4, p. 580-587 8 p.

    Research output: Contribution to journalArticle

  6. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity

    Hughes, K. A., Webster, S. P. & Walker, B. R., Apr 2008, In : Expert opinion on investigational drugs. 17, 4, p. 481-96 16 p.

    Research output: Contribution to journalLiterature review

  7. 11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease

    Anderson, A. & Walker, B. R., Sep 2013, In : Drugs. 73, 13, p. 1385-1393 9 p.

    Research output: Contribution to journalArticle

  8. 11β-HSD1 suppresses cardiac fibroblast CXCL2, CXCL5 and neutrophil recruitment to the heart post MI

    Mylonas, K. J., Turner, N. A., Bageghni, S. A., Kenyon, C. J., White, C. I., McGregor, K., Kimmitt, R. A., Sulston, R., Kelly, V., Walker, B. R., Porter, K. E., Chapman, K. E. & Gray, G. A., 1 Jun 2017, In : Journal of Endocrinology. 233, 3, p. 315-327 13 p.

    Research output: Contribution to journalArticle

  9. 11β-Hydroxysteroid Dehydrogenase Activity in the Brain Does Not Contribute to Systemic Interconversion of Cortisol and Cortisone in Healthy Men

    Kilgour, A. H. M., Semple, S., Marshall, I., Andrews, P., Andrew, R. & Walker, B. R., Feb 2015, In : Journal of Clinical Endocrinology & Metabolism. 100, 2, p. 483-489 7 p.

    Research output: Contribution to journalArticle

  10. 11β-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo

    Mitic, T., Shave, S., Semjonous, N., McNae, I., Cobice, D. F., Lavery, G. G., Webster, S. P., Hadoke, P. W. F., Walker, B. R. & Andrew, R., 1 Jul 2013, In : Biochemical Pharmacology. 86, 1, p. 146-153 8 p.

    Research output: Contribution to journalArticle

  11. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis

    Kipari, T., Hadoke, P. W. F., Iqbal, J., Man, T-Y., Miller, E., Coutinho, A. E., Zhang, Z., Sullivan, K. M., Mitic, T., Livingstone, D. E. W., Schrecker, C., Samuel, K., White, C. I., Bouhlel, M. A., Chinetti-Gbaguidi, G., Staels, B., Andrew, R., Walker, B. R., Savill, J. S., Chapman, K. E. & 1 others, Seckl, J. R., Apr 2013, In : The FASEB Journal. 27, 4, p. 1519-1531 13 p.

    Research output: Contribution to journalArticle

  12. 11β-hydroxysteroid dehydrogenase type 1, brain atrophy and cognitive decline

    MacLullich, A. M. J., Ferguson, K. J., Reid, L. M., Deary, I. J., Starr, J., Wardlaw, J. M., Walker, B. R., Andrew, R. & Seckl, J. R., Jan 2012, In : Neurobiology of Aging. 33, 1, p. 207.e1–207.e8 8 p.

    Research output: Contribution to journalArticle

  13. 19F-magnetic resonance spectroscopy as a tool to quantify 11[beta]-hydroxysteroid dehydrogenase activity in vivo

    Naredo-Gonzalez, G., Jansen, M., Upreti, R., Semple, S., Merrifield, G., Sutcliffe, O., Hansen, M., Marshall, I., Andrew, R. & Walker, B., 2013, In : Endocrine Abstracts. p. 1-1

    Research output: Contribution to journalArticle

  14. 3-DIMENSIONAL EX VIVO ANALYSIS BY OPTICAL PROJECTION TOMOGRAPHY DEMONSTRATES THAT EXOGENOUS GLUCOCORTICOIDS AUGMENT ATHEROGENESIS IN APOE-/- MICE

    Low, L., Kirkby, N. S., Seckl, J. R., Walker, B. R. & Hadoke, P. W. F., 15 Nov 2009, In : Heart. 95, 22, p. - 2 p.

    Research output: Contribution to journalMeeting abstract

  15. 5 alpha-Reductase Type 1 Deficiency or Inhibition Predisposes to Insulin Resistance, Hepatic Steatosis, and Liver Fibrosis in Rodents

    Livingstone, D. E. W., Barat, P., Di Rollo, E. M., Rees, G. A., Weldin, B. A., Rog-Zielinska, E. A., MacFarlane, D. P., Walker, B. R. & Andrew, R., 22 Jan 2015, In : Diabetes . 64, 2, p. 447-458 12 p.

    Research output: Contribution to journalArticle

  16. 5alpha-reduced glucocorticoids, novel endogenous activators of the glucocorticoid receptor

    McInnes, K. J., Kenyon, C. J., Chapman, K. E., Livingstone, D. E. W., Macdonald, L. J., Walker, B. R. & Andrew, R., 2004, In : Journal of Biological Chemistry. 279, 22, p. 22908-12 5 p.

    Research output: Contribution to journalArticle

Previous 1 2 3 4 5 6 7 8 ...13 Next